UNICREDIT BANK/CALL/AMGEN/420/0.1/15.01.25

UNICREDIT BANK/CALL/AMGEN/420/0.1/15.01.25 Stock

DE000HD21R79

Market Closed - Boerse Frankfurt Warrants 13:25:07 2024-05-31 EDT
0.33 ^EUR	+3.12%

1 month	+175.00%
3 months	+135.71%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart AMGEN INC.

Chart UNICREDIT BANK/CALL/AMGEN/420/0.1/15.01.25

Latest news about AMGEN INC.

Amgen : 2024 Annual Meeting of Stockholders Presentation	05-31	PU
US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment	05-28	RE
Amgen's Rare-Disease Treatment Biosimilar Bkemv Gets FDA Approval	05-28	DJ
Weight-loss drug forecasts jump to $150 billion as supply grows	05-28	RE

More news

Quotes 5-day view

Date	Price	Change
24-05-31	0.33	+3.13%
24-05-30	0.32	+14.29%
24-05-29	0.28	-3.45%
24-05-28	0.29	-19.44%
24-05-27	0.36	-7.69%

Real-time Boerse Frankfurt Warrants

Last update May 31, 2024 at 01:25 pm

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	AMGEN INC.
Issuer	UniCredit
WKN	HD21R7
ISIN	DE000HD21R79
Date issued	2024-01-23
Strike	420 $
Maturity	2025-01-15 (228 Days)
Parity	10 : 1
Emission price	0.59 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	0.8 €
Lowest since issue	0.007 €
Spread	0.03 €
Spread %	8.11%

Company Profile

Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.3% of net sales.

Sector

More about the company